Clinical Trial Update: Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on pharmacokinetics of calcineurin and mTOR inhibitors in HIV-1 infected kidney transplant recipients after switch to BIC/FTC/TAF.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Kidney Transplant Recipients

Drugs mentioned

• BIC/FTC/TAF (bictegravir/emtricitabine/tenofovir alafenamide)
• Calcineurin inhibitors
• mTOR inhibitors (mTOR inhibitors)

Snippet

Sponsor: Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | Conditions: HIV-infected Patient Kidney Transplant Recipient | Phase 4 | Status: UNKNOWN